The rising popularity in GLP-1 agonists for diabetes has sparked a debate about delivery methods : transdermal systems versus tablets . Traditionally , GLP-1 treatments were only available in oral form, but the introduction of patches offers a new choice . Transdermal systems might benefit indivi